A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity.

Peter De BoerWayne C DrevetsHany RofaelPeter D van der ArkJustine M KentIva KezicSilvia ParapaticsGeorg DorffnerJoop van GervenHeike BenešChristian KeicherHolger JahnDavid J SeidenRemy Luthringer

Published in: Journal of psychopharmacology (Oxford, England) (2018)

Sleep efficiency was increased with seltorexant treatment compared with placebo. Treatment with seltorexant resulted in a prolonged total sleep time, shorter latency to persistent sleep and wake after sleep onset. There were no unexpected safety findings.

Keyphrases

sleep quality
physical activity
mental health
randomized controlled trial
clinical trial
depressive symptoms
open label
combination therapy
smoking cessation
study protocol
placebo controlled